Essential thrombocytosis

Essential thrombocytosis

DiseaseDisorder infobox
Name = Essential thrombocytosis
ICD10 = ICD10|D|75|2|d|70, ICD10|D|47|3|d|37
ICD9 = ICD9|238.71
ICDO = 9962/3

Caption =
OMIM = 187950
DiseasesDB = 4522
MedlinePlus = 000543
eMedicineSubj = med
eMedicineTopic = 2266
MeshID = D013920

Essential thrombocytosis (ET, also known as essential thrombocythemia) is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow in the absence of an alternative cause. In some cases this disorder may be progressive, and rarely may evolve into acute myeloid leukemia or myelofibrosis. It is one of four myeloproliferative disorders.


Essential thrombocytosis is diagnosed at a rate of about 2 to 3 per 100,000 individuals annually. [cite journal | author = Mesa R, Silverstein M, Jacobsen S, Wollan P, Tefferi A | title = Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995 | journal = Am J Hematol | volume = 61 | issue = 1 | pages = 10–5 | year = 1999 | pmid = 10331505 | doi = 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I] [cite journal | author = Kutti J, Ridell B | title = Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis | journal = Pathol Biol (Paris) | volume = 49 | issue = 2 | pages = 164–6 | year = 2001 | pmid = 11317963] The disease usually affects middle aged to elderly individuals, with an average age at diagnosis of 50-60 years, although it can affect children and young adults as well. [Hoffman: Hematology: Basic Principles and Practice, 4th ed., 2005 Churchill Livingstone, Chapter 71.]


The pathologic basis for this disease is unknown. However, essential thrombocytosis resembles polycythemia vera in that cells of the megakaryocytic series are more sensitive to growth factors. Platelets derived from the abnormal megakaryocytes do not function properly, which contributes to the clinical features of bleeding and thrombosis.

In 2005, a mutation in the JAK2 kinase (V617F) was found by multiple research groups cite journal | author=Kralovics R, Passamonti F, Buser AS, Teo SS, et al |title=A gain-of-function mutation of JAK2 in myeloproliferative disorders| journal=N Engl J Med |date=2005 |volume=352|issue=17 |pages=1779–90 | doi=10.1056/NEJMoa051113 |pmid=15858187] cite journal |author=Baxter EJ, Scott LM, Campbell PJ, "et al" |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=] cite journal |author=Levine RL, Wadleigh M, Cools J, "et al" |title=Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis |journal=Cancer Cell |volume=7 |issue=4 |pages=387–97 |year=2005 |pmid=15837627 |doi=10.1016/j.ccr.2005.03.023 |url=] to be associated with essential thrombocytosis in around 30% of cases. "JAK2" is a member of the Janus kinase family. This mutation may be helpful in making a diagnosis or as a target for future therapy.

Clinical features

The major symptoms are bleeding and thrombosis. Other symptoms include epistaxis (nosebleeds) and bleeding from gums and gastrointestinal tract. One characteristic symptom is throbbing and burning of the hands and feet due to the occlusion of small arterioles by platelets (erythromelalgia). An enlarged spleen (splenomegaly) may be found on examination.

Diagnostic criteria

The diagnosis of essential thrombocytosis requires the presence of a persistent thrombocytosis of greater than 600 x109/L in the absence of an alternative cause.

The following revised diagnostic criteria for essential thrombocytosis were proposed in 2005 cite journal |author=Campbell PJ, Green AR |title=Management of polycythemia vera and essential thrombocythemia |journal=Hematology Am Soc Hematol Educ Program |volume= |issue= |pages=201–8 |year=2005 |pmid=16304381 |doi=10.1182/asheducation-2005.1.201 |url=] . The diagnosis requires the presence of both A criteria together with B3 to B6, or of criterion A1 together with B1 to B6.

* A1. Platelet count > 600 x 109/L for at least 2 months
* A2. Acquired V617F JAK2 mutation present
* B1. No cause for a reactive thrombocytosis
** normal inflammatory indices
* B2. No evidence of iron deficiency
** stainable iron in the bone marrow or normal red cell mean corpuscular volume
* B3. No evidence of polycythemia vera
** hematocrit < midpoint of normal range or normal red cell mass in presence of normal iron stores
* B4. No evidence of chronic myeloid leukemiaBut the Philadelphia chromosome may be present in up to 10% of cases. Patients with the Philadelphia chromosome have a potential for the development of acute leukemia, especially acute lymphocytic leukemia.
* B5. No evidence of myelofibrosis
** no collagen fibrosis and ≤ grade 2 reticulin fibrosis (using 0–4 scale)
* B6. No evidence of a myelodysplastic syndrome
** no significant dysplasia
** no cytogenetic abnormalities suggestive of myelodysplasia


Not all patients will require treatment at presentation. In those who are at increased risk of thrombosis or bleeding (older age, prior history of bleeding or thrombosis, or very high platelet count), reduction of the platelet count to the normal range can be achieved using hydroxyurea (also known as hydroxycarbamide), interferon-α or anagrelide. Low-dose aspirin is widely used to reduce the risk of thrombosis, but there may be an increased risk of bleeding if aspirin is initiated whilst the platelet count is very high.

The PT1 study cite journal |author=Harrison CN, Campbell PJ, Buck G, "et al" |title=Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia |journal=N. Engl. J. Med. |volume=353 |issue=1 |pages=33–45 |year=2005 |pmid=16000354 |doi=10.1056/NEJMoa043800 |url=] compared hydroxyurea in combination with aspirin to anagrelide in combination with Aspirin as initial therapy for essential thrombocytosis. Hydroxyurea was superior, with lower risk of arterial thrombosis, lower risk of severe bleeding and lower risk of transformation to myelofibrosis (although the rate of venous thrombosis was higher with hydroxycarbamide than with anagrelide).

In rare cases where patients have life-threatening complications, the platelet count can be reduced rapidly using platelet apheresis (a procedure that removes platelets from the blood directly).


Essential thrombocytosis is sometimes described as a slowly progressive disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic events.

However, well-documented medical regimes can reduce and control the number of platelets, which reduces the risk of these thrombotic or haemorrhagic events. The lifespan of a well controlled ET person is well within the expected range for a person of similar age but without ET.

pecial care related to pregnancy

Hydroxyrea and anagrelide are counter-indicated during pregnancy and nursing. There is current debate as to the safety of interferon during pregnancy and nursing. Essential thrombocytosis can be linked with increased risk of spontaeous abortion or miscarriage in the first trimester of pregnancy. Throughout pregnancy, close monitoring of the mother for thrombosis and placenta is recommended to ensure blood clots are caught. Post partum, often daily injections of low dose low molecular weight heparin (e.g. enoxaparin) are prescribed for several weeks as this is a period where the mother is at higher risk of developing a blood clot.


External links

* [ Cancerbackup Essential Thrombocytosis page]
* [ CMPD Education Foundation]
* [ MPD Foundation and Research Alliance - Register for a free newsletter]
* [ Overview of Agrylin, the tradename for anagrelide hydrochloride]

Wikimedia Foundation. 2010.

Игры ⚽ Поможем решить контрольную работу

Look at other dictionaries:

  • essential thrombocytosis — An increased number of thrombocytes (platelets) in the blood, without a known cause. Also called essential thrombocythemia …   English dictionary of cancer terms

  • Thrombocytosis — Infobox Disease Name = PAGENAME Caption = DiseasesDB = 27591 ICD10 = ICD9 = ICD9|289.9 ICDO = OMIM = MedlinePlus = eMedicineSubj = med eMedicineTopic = 2267 eMedicine mult = eMedicine2|ped|2238 MeshID = Thrombocytosis is the presence of high… …   Wikipedia

  • essential thrombocythemia — An increased number of thrombocytes (platelets) in the blood, without a known cause. Also called essential thrombocytosis …   English dictionary of cancer terms

  • primary thrombocytosis — essential thrombocythemia …   Medical dictionary

  • List of diseases (E) — A list of diseases in the English wikipedia.DiseasesTOC Ea Eb* EAF * Eales disease * Ear, patella, short stature syndrome * Earlobes thickened conductive deafness * Ebola hemorrhagic fever * Ebstein s anomalyEcEcc Ecp* Eccentrochondrodysplasia *… …   Wikipedia

  • Myeloproliferative disease — Classification and external resources ICD 10 D47.1 ICD 9 205.1 …   Wikipedia

  • Platelet — Platelets, or thrombocytes, are small cytoplasmic bodies derived from cells. They circulate in the blood of mammals and are involved in hemostasis leading to the formation of blood clots. Like red blood cells, platelets have no nucleus. If the… …   Wikipedia

  • Myelodysplastic syndrome — Classification and external resources ICD 10 D46 ICD 9 238.7 …   Wikipedia

  • Chronic myelogenous leukemia — Classification and external resources The Philadelphia chromosome as seen by metaphase FISH. ICD 10 C92.1 …   Wikipedia

  • Hydroxyurea — or hydroxycarbamide (the latter being the recommended International Nonproprietary Name) is an antineoplastic drug used in hematological malignancies, specifically polycythemia vera and essential thrombocytosis. It is also used to reduce the rate …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”